KR20230065499A - A mushroom-mycelium fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof - Google Patents
A mushroom-mycelium fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof Download PDFInfo
- Publication number
- KR20230065499A KR20230065499A KR1020210151121A KR20210151121A KR20230065499A KR 20230065499 A KR20230065499 A KR 20230065499A KR 1020210151121 A KR1020210151121 A KR 1020210151121A KR 20210151121 A KR20210151121 A KR 20210151121A KR 20230065499 A KR20230065499 A KR 20230065499A
- Authority
- KR
- South Korea
- Prior art keywords
- mushroom mycelium
- protopanaxatriol
- protopanaxadiol
- fermented
- ginsenosides
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 241000208340 Araliaceae Species 0.000 title claims abstract description 50
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 50
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 48
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 48
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 title claims abstract description 44
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 title claims abstract description 44
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 title claims abstract description 43
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 title claims abstract description 43
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 title claims abstract 12
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 title claims abstract 11
- HJRVLGWTJSLQIG-UHFFFAOYSA-N (20S)-protopanaxatriol-20-alpha-L-arabinopyranosyl(1->6)-beta-D-glucopyranoside Natural products C1CC(C2(CC(O)C3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O HJRVLGWTJSLQIG-UHFFFAOYSA-N 0.000 title claims description 4
- HJRVLGWTJSLQIG-ABNMXWHVSA-N Ginsenoside F3 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@H](O)[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O HJRVLGWTJSLQIG-ABNMXWHVSA-N 0.000 title claims description 4
- VAXXNBLRJUUBPR-UHFFFAOYSA-N ginsenoside F3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(CC23C)OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C VAXXNBLRJUUBPR-UHFFFAOYSA-N 0.000 title claims description 4
- 230000001965 increasing effect Effects 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 76
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 56
- 238000000855 fermentation Methods 0.000 claims abstract description 41
- 230000004151 fermentation Effects 0.000 claims abstract description 40
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 241000283708 Capra aegagrus Species 0.000 claims description 26
- 244000068988 Glycine max Species 0.000 claims description 13
- 235000010469 Glycine max Nutrition 0.000 claims description 13
- 241000190633 Cordyceps Species 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 241000283707 Capra Species 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 238000010025 steaming Methods 0.000 claims description 5
- 230000000887 hydrating effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 102000019280 Pancreatic lipases Human genes 0.000 abstract description 9
- 108050006759 Pancreatic lipases Proteins 0.000 abstract description 9
- 229940116369 pancreatic lipase Drugs 0.000 abstract description 9
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 4
- PYXFVCFISTUSOO-VUFVRDRTSA-N (20R)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-VUFVRDRTSA-N 0.000 description 41
- SHCBCKBYTHZQGZ-PHFGEWBZSA-N (3s,5r,6s,8r,9r,10r,12r,13r,14s,17s)-17-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,6,12-triol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-PHFGEWBZSA-N 0.000 description 38
- 230000000052 comparative effect Effects 0.000 description 30
- 239000000243 solution Substances 0.000 description 29
- 239000000523 sample Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 16
- 229940089161 ginsenoside Drugs 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 11
- 230000002292 Radical scavenging effect Effects 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 229930003935 flavonoid Natural products 0.000 description 8
- 150000002215 flavonoids Chemical class 0.000 description 8
- 235000017173 flavonoids Nutrition 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 244000046052 Phaseolus vulgaris Species 0.000 description 6
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 6
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 240000001462 Pleurotus ostreatus Species 0.000 description 3
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000001965 potato dextrose agar Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 244000252132 Pleurotus eryngii Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-FDDSVCGKSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O ZTQSADJAYQOCDD-FDDSVCGKSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- ZUXNULGHCOXCFL-UHFFFAOYSA-N 2-(4-tert-butyl-2,6-dimethylphenyl)acetonitrile Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC#N ZUXNULGHCOXCFL-UHFFFAOYSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 240000006499 Flammulina velutipes Species 0.000 description 1
- 235000016640 Flammulina velutipes Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- BGHNZAWRRWLKPO-UHFFFAOYSA-N Ginsenoside F1 Natural products CC(=C)CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C BGHNZAWRRWLKPO-UHFFFAOYSA-N 0.000 description 1
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 1
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- XNGXWSFSJIQMNC-FIYORUNESA-N ginsenoside F1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@H](O)[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XNGXWSFSJIQMNC-FIYORUNESA-N 0.000 description 1
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Agronomy & Crop Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 강화된 산양삼새싹 버섯균사체 발효조성물 및 그 제조방법에 관한 것으로, 더 상세하게는 산양삼새싹을 동충하초버섯 또는 팽이버섯의 균사체로 발효하여 제조한 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올과 항산화 활성, 알파-글루코시다아제 저해활성, 및 췌장-리파아제 저해활성이 현저히 증진된 발효조성물 및 그 제조방법에 관한 것이다.The present invention relates to a fermented composition of wild goat sprout mushroom mycelium enriched with ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol and a method for producing the same, in more detail ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol and antioxidant activity, alpha-glucose prepared by fermenting wild goat sprouts with mycelium of cordyceps or enoki mushrooms. It relates to a fermented composition with significantly enhanced sidase inhibitory activity and pancreatic-lipase inhibitory activity and a method for producing the same.
삼(Ginseng)은 재배환경에 따른 인위적인 성장과 자연적인 성장의 차이와 형태학적 차이 등에 따라 인삼(人蔘), 산삼(山蔘), 또는 산양삼(山羊蔘)으로 구분한다. 특히 산양삼은 오가피과에 속하며 다년생 초목인 인삼(Panax ginseng)이 산간의 삼림하의 야생상태에서 자연적으로 성장한 산삼의 씨앗이나 유삼을 인위적으로 산에서 재배한 것을 말하며 이들을 산양삼이라 한다. 인삼의 경우에는 대부분 노두(머리 부분)가 3-7개 정도이나 산양삼은 연령에 따라 그 이상인 것이 많으며 인삼의 뿌리는 굵고 짧으나 산양삼은 길고 가늘다. 산양삼(山養蔘)이란 「산지관리법」 제2조 1호의 산지에서 재배하고 「임업 및 산촌 진흥촉진에 관한 법률」 제18조의 4에 따른 품질검사에 합격한 오갈피나무과(科) 인삼속(人蔘屬) 식물을 말한다. 산양삼은 고려인삼(高麗人蔘)의 인삼종으로 Panax ginseng C.A. Mey.라는 학명으로 불리며, 속명인 'Panax'는 만병통치약을 뜻한다. Ginseng is classified into ginseng, wild ginseng, or wild ginseng according to the difference between artificial growth and natural growth according to the cultivation environment and morphological differences. In particular, Sanyangsam belongs to the Ogapicaceae family, and Panax ginseng , a perennial plant, refers to wild ginseng seeds or young ginseng grown naturally in the wild under mountainous forests, which are artificially cultivated in the mountains, and they are called Sanyangsam. In the case of ginseng, most of them have 3-7 outcrops (head part), but sanyangsam has more than that depending on age, and the root of ginseng is thick and short, but sanyangsam is long and thin. Sanyangsam (山養蔘) is a ginseng genus of the ginseng family that has been cultivated in a mountainous area under Article 2,
진세노사이드는 트리터펜노이드(triterpenoid)의 담마란네(dammarane)계의 인삼 속의 식물에만 존재하는 특유 사포닌이다. 기본 골격의 탄소 3, 6, 및 20번의 위치에 글루코스, 자일로스 및 람노스 등의 당을 결하는 형태의 구조를 가지며 이들은 프로토파낙사디올(protopanaxadiol), 프로토파낙사트리올(protopanaxatriol), 올래놀익산(oleanolic acid), 및 옥틸롤(octillol) 계열로 나눠지며, 약성이 매우 온화하고 과량투여에 의한 독성이 없으며 용혈작용이 거의 없는 것으로 알려졌다. 프로토파낙사디올 계열은 진세노사이드 Rb1, Rb2, Rb3, Rc, Rd, 및 Rg1 등이 있으며, 프로토파낙사트리올 계열은 진세노사이드 Re, Rf, Rg1, 및 Rg2 등이 있다. 이러한 진세노사이드들은 여러 효능들이 알려져 있다. 대표적으로 항암, 항당뇨작용 및 면역기능 조절작용 등에 효능이 있다고 보고되었다. 보통 인삼은 뿌리만 식용으로 사용되고 있으며 이는 재배 년 수가 지날수록 잎의 경질화 등에 의해 식용이 어렵기 때문이다. 하지만 광합성과 관련이 있는 인삼의 잎에도 적지 않은 진세노사이드가 함유되어 있다고 보고되었다. Ginsenoside is a unique saponin that exists only in plants of the genus ginseng of the dammarane family of triterpenoids. It has a structure in which sugars such as glucose, xylose, and rhamnose are linked to
산양삼새싹(mountain-cultivated ginseng sprout)은 산양삼 3년근 이상을 해발 500m 이상 숲에서 5월에서 6월 사이 잎과 줄기 자란 것이나 혹은 산양삼 3년근 이상을 일정한 환경이 제어되는 시설(스마트팜 혹은 식물공장)에서 20~120일 동안 잎과 줄기 자란 것을 칭한다. 산양삼새싹은 재배동안에는 환경이 제어되는 시설에서는 연중생산 가능하고 재배 기간의 짧아서 산업적 이용면에서 장점이 있어, 이의 가공품의 개발이 요구되고 있다.Mountain-cultivated ginseng sprout (mountain-cultivated ginseng sprout) is a facility (smart farm or plant factory) that grows more than 3 years old wild ginseng leaves and stems between May and June in a forest at an altitude of 500m or more, or more than 3 years old wild ginseng. It refers to the growth of leaves and stems for 20 to 120 days. Wild ginseng sprouts can be produced year-round in facilities where the environment is controlled during cultivation, and the cultivation period is short, so there is an advantage in terms of industrial use, and the development of processed products is required.
버섯균사체는 솜털모양의 가는 실같은 형태로 부식토 또는 고목과 같은 유기물 속에서 기생 및 부생생활을 하는 곰팡이로서, 식물의 뿌리, 줄기, 잎에 해당된다. 도라지를 버섯균사초로 고체발효하여 총페놀성화합물과 베타글루칸을 증가시키는 방법 (등록특허 10-1884298호) 및 우수한 풍미와 증진된 기능성을 갖는 혼합곡물의 송이버섯 균사체 발효조성물 (등록특허 10-1889596호)이 개시되어 있다.Mushroom mycelium is a fungus that lives as a parasitic and byproduct in organic matter such as humus soil or dead wood in the form of a fluffy thin thread, and corresponds to the roots, stems, and leaves of plants. A method for increasing total phenolic compounds and beta-glucan by solid fermentation of bellflower with mushroom mycelium (Registration Patent No. 10-1884298) and Matsutake mushroom mycelium fermented composition of mixed grains having excellent flavor and enhanced functionality (Registration Patent No. 10-1889596 Ho) is disclosed.
그러나 산양삼새싹을 동충하초버섯 또는 팽이버섯의 균사체에 의한 성공적인 발효의 전례가 없을 뿐만 아니라, 특히 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 현저히 증진된 산양삼새싹 버섯균사체 발효조성물은 개발된 바 없다.However, there is no precedent for successful fermentation of wild goat shoots by the mycelium of Cordyceps sinensis or Enoki mushroom, especially ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol. This significantly improved fermented goat mushroom mycelium composition has not been developed.
이에 본 발명자들은 종래 기술의 요구에 부응하기 위한 연구를 지속한 결과, 산양삼새싹을 동충하초버섯 또는 팽이버섯의 균사체로 발효한 경우, 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 현저히 증진됨을 확인하고 본 발명을 완성하게 되었다.Accordingly, the inventors of the present invention continued research to meet the needs of the prior art, and as a result, when fermenting goat ginseng sprouts with mycelium of cordyceps sinensis or enoki mushroom, ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, The present invention was completed after confirming that protopanaxatriol and protopanaxadiol were remarkably enhanced.
따라서 본 발명의 목적은 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 강화된 산양삼새싹의 버섯균사체 발효조성물을 제공하는 것이다.Therefore, an object of the present invention is to provide a mushroom mycelium fermented composition of wild goat sprouts enriched with ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol.
본 발명의 또 다른 목적은 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 강화된 버섯균사체 발효조성물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for producing a mushroom mycelium fermentation composition enriched in ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol.
본 발명의 또 다른 목적은 본 발명의 산양삼새싹의 버섯균사체 발효조성물을 포함하는 기능성식품을 제공하는 것이다.Another object of the present invention is to provide a functional food containing the mushroom mycelium fermented composition of wild ginseng sprouts of the present invention.
본 발명의 또 다른 목적은 본 발명의 산양삼새싹의 버섯균사체 발효조성물을 포함하는 화장품을 제공하는 것이다.Another object of the present invention is to provide a cosmetic comprising the fermented composition of mushroom mycelium of wild ginseng sprouts of the present invention.
상기 목적을 달성하기 위하여, 본 발명은 산양삼새싹 및 콩의 혼합물을 버섯균사체로 발효하여 제조된 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 증진된 산양삼새싹의 버섯균사체 발효조성물을 제공한다.In order to achieve the above object, the present invention is ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxa prepared by fermenting a mixture of goat shoots and soybeans into mushroom mycelium. Provides a diol-enhanced mushroom mycelium fermentation composition of wild ginseng sprouts.
본 발명에서 산양삼새싹은 산양삼 3년근 이상을 해발 500m 이상 숲에서 5월에서 6월 사이 잎과 줄기 자란 것이나 혹은 산양삼 3년근 이상을 일정한 환경이 제어되는 시설(스마트팜 혹은 식물공장)에서 20~120일 동안 잎과 줄기 자란 것을 칭하는 것으로, 바람직하게는 산양삼 3년근 이상을 해발 500m 이상 숲에서 5월 및 일정한 환경이 제어되는 시설에서 25~45일 동안 생육시켜 잎과 줄기가 자란 것을 사용하는 것이 바람직하다.In the present invention, wild ginseng sprouts grow more than 3 years old wild ginseng in a forest at an altitude of 500m or more from May to June, or grow more than 3 years old wild ginseng in a facility where a certain environment is controlled (smart farm or plant factory) 20 to 120 It refers to growing leaves and stems for days, preferably growing more than 3 years of wild ginseng in a forest at an altitude of 500m or more in May and in a facility where a certain environment is controlled for 25 to 45 days. It is preferable to use the grown leaves and stems do.
본 발명의 혼합물에서 산양삼새싹은 90~94 중량%, 콩은 6~10 중량%로 포함되는 것이 바람직하고, 가장 바람직하게는 산양삼새싹 90 중량% 및 콩 10 중량%가 포함된다. In the mixture of the present invention, 90 to 94% by weight of wild ginseng sprouts and 6 to 10% by weight of beans are preferably included, and most preferably, 90% by weight of wild ginseng sprouts and 10% by weight of soybeans are included.
산양삼새싹의 함량이 상기 범위를 벗어나면, 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올, 및 프로토파낙사디올의 함량이 떨어지며, 콩의 함량이 상기 범위를 벗어나면 버섯균사체의 균사 성장이 충분하지 않을 수 있다. 버섯균사체의 균사 성장 정도와 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올의 함량을 모두 고려할 때 산양삼새싹 : 콩의 중량비는 9 : 1인 것이 가장 바람직하다.When the content of wild goat sprouts is out of the above range, the content of ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol falls, and the content of soybeans falls within the above range. If it is out of range, mycelial growth of mushroom mycelium may not be sufficient. Considering both the degree of mycelial growth of mushroom mycelium and the contents of ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol, the weight ratio of wild goat sprouts: soybeans was 9: 1. It is most preferable to be
본 발명에서 콩은 주로 버섯균사체의 균사 생육에 필요한 질소원의 역할을 하면서도 버섯균사체의 발효(물질전환작용)를 증진시키는 기능도 한다. In the present invention, beans mainly serve as a nitrogen source necessary for the growth of mushroom mycelium, but also function to enhance the fermentation (material conversion action) of mushroom mycelium.
본 발명에서 산양삼새싹은 세척한 후 건조하고 세절하여 50~55℃에서 2~3일간 건조하여 사용하는 것이 바람직하며, 콩은 세척하고 물기를 제거한 것을 사용한다. In the present invention, it is preferable to use goat ginseng sprouts after washing, drying, cutting, and drying at 50 to 55 ° C for 2 to 3 days, and beans are washed and dried.
본 발명에서 ‘버섯균사체’는 동충하초버섯(Cordyceps militaris) 또는 팽이버섯(Flammulina velutipes)의 균사체를 사용하는 것이 바람직하다. In the present invention, the 'mushroom mycelium' is preferably a mycelium of Cordyceps militaris or Flammulina velutipes .
본 발명에서 ‘발효’는 동충하초버섯 또는 팽이버섯의 균사체를 종균으로 사용하여 발효하는 것을 의미한다. 산양삼새싹 및 콩의 혼합물을 동충하초버섯 또는 팽이버섯의 균사체로 발효시, 놀랍게도 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 현저히 증진되었다 (표 1, 도 2 및 도 3). In the present invention, 'fermentation' means fermentation using the mycelium of Cordyceps sinensis or Enoki mushroom as a spawn. When the mixture of wild goat sprouts and soybeans was fermented with the mycelium of Cordyceps sinensis or Enoki mushroom, ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol were remarkably increased. (Table 1, Figures 2 and 3).
본 발명에서 동충하초버섯 또는 팽이버섯의 균사체는 산양삼새싹 및 콩의 혼합물에 3~10%(v/w) 농도로 접종하여 20~30℃에서 8~12일간 발효시키는 것으로 수행될 수 있다. 가장 바람직하게는 10일간 발효한다. In the present invention, the mycelium of Cordyceps sinensis or Enoki mushroom can be performed by inoculating a mixture of wild goat sprouts and beans at a concentration of 3 to 10% (v / w) and fermenting at 20 to 30 ° C. for 8 to 12 days. Most preferably fermented for 10 days.
동충하초버섯 또는 팽이버섯의 버섯균사체 접종량이 3%(v/w) 미만일 경우에는 발효 속도가 지연될 수 있고 10%(v/w) 초과시에는 균사체 증식 속도가 빨라 전환율이 낮을 수 있으며, 발효 온도가 20℃ 미만일 경우 발효기간이 길어져 잡균의 오염을 초래하고 30℃를 초과할 경우에는 균사체의의 생육이 저하될 수 있고, 발효 기간이 8일 미만일 경우 발효가 충분하지 않아 생리활성물질 등의 생성이 저조하게 될 수 있으며, 12일을 초과한 경우는 과발효에 의해 생리활성물질이 분해될 수 있다.If the inoculation amount of mushroom mycelium of Cordyceps sinensis or Enoki mushroom is less than 3% (v/w), the fermentation rate may be delayed, and if it exceeds 10% (v/w), the mycelial growth rate may be fast, resulting in low conversion rate, and the fermentation temperature may be lowered. If the fermentation period is less than 20 ℃, the fermentation period is prolonged, resulting in contamination of various germs, and if it exceeds 30 ℃, the growth of mycelia may be reduced. If it exceeds 12 days, physiologically active substances may be decomposed by over-fermentation.
본 발명에서 산양삼새싹 및 콩의 혼합물은 발효 전에, 5~10배(v/v)의 물을 첨가하여 5~8시간 수화시켜 수분이 40~50% 정도 되게 조정한 후 100~120℃에서 30~60분 증자처리하는 것이 바람직하다. 가장 바람직하게는 120℃에서 30분 증자한다. In the present invention, before fermentation, the mixture of wild ginseng sprouts and soybeans is hydrated for 5 to 8 hours by adding 5 to 10 times (v / v) of water to adjust the moisture to about 40 to 50%, and then ~60 min steaming is preferred. Most preferably, it is steamed for 30 minutes at 120°C.
본 발명에서 수화 처리 시 수분 함량이 40% 이하의 경우, 동충하초버섯 및 팽이버섯의 균사 생육이 원활하지 않으며, 수분 함량이 50% 이상의 경우 동충하초버섯 및 팽이버섯의 균사 생육뿐만 아니라 세균 등의 증식이 이루어질 수 있다. 한편, 증자 30분 이하 처리 시 살균이 완벽하게 이루어지 않아 동충하초버섯 및 팽이버섯의 균사체 이외에 세균 등의 증식에 의하여 이상발효가 진행될 수 있고 60분 이상 처리 시 영양성분 파괴되는 과다하게 진행될 수 있다.In the present invention, when the moisture content is 40% or less during the hydration treatment, the growth of mycelia of cordyceps and enoki mushrooms is not smooth, and when the moisture content is 50% or more, not only the growth of mycelia of cordyceps and enoki mushrooms, but also the growth of bacteria, etc. It can be done. On the other hand, when steamed for 30 minutes or less, sterilization is not completely performed, so abnormal fermentation may proceed due to the proliferation of bacteria, etc. in addition to the mycelium of cordyceps and enoki mushrooms, and nutrients may be destroyed excessively when treated for 60 minutes or more.
본 발명에 따른 산양삼새싹의 버섯균사체 발효조성물은 진세노사이드 F3를 0.23 mg/g 이상, Rg2를 1.31 mg/g 이상, F1을 1.27 mg/g 이상, 프로토파낙사트리올을 0.28 mg/g 이상, Rd을 6.59 mg/g 이상, Rd2를 1.10 mg/g 이상, F2를 2.48 mg/g 이상, Rg3를 1.16 mg/g 이상, 및 프로토파낙사디올을 4.53 mg/g 이상 함유한다 (표 1). The mushroom mycelium fermented composition of wild goat sprouts according to the present invention contains ginsenoside F3 of 0.23 mg/g or more, Rg2 of 1.31 mg/g or more, F1 of 1.27 mg/g or more, and protopanaxatriol of 0.28 mg/g or more. , Rd of 6.59 mg/g or more, Rd2 of 1.10 mg/g or more, F2 of 2.48 mg/g or more, Rg3 of 1.16 mg/g or more, and protopanaxadiol of 4.53 mg/g or more (Table 1) .
본 발명에 따른 산양삼새싹의 버섯균사체 발효조성물은 프로토파낙사트리올 계열, 프로토파낙사디올 계열, 및 총 진세노사이드를 각각 3.17 mg/g 이상, 22.65 mg/g 이상, 및 25.82 mg/g 이상 함유한다 (도 3). The mushroom mycelium fermented composition of wild goat sprouts according to the present invention contains 3.17 mg/g or more, 22.65 mg/g or more, and 25.82 mg/g or more of protopanaxatriol series, protopanaxadiol series, and total ginsenosides, respectively. contains (Fig. 3).
본 발명에 따른 산양삼새싹의 버섯균사체 발효조성물은 프로토파낙사트리올 계열, 프로토파낙사디올 계열, 및 총 진세노사이드의 함량이 가공전 혼합물(비교예 1)에 비하여 각각 약 2.4배 이상, 약 3.9배 이상 및 약 3.6배 이상 증진된다 (도 3). The mushroom mycelium fermented composition of wild goat sprouts according to the present invention has a content of protopanaxatriol series, protopanaxadiol series, and total ginsenosides of about 2.4 times or more, respectively, compared to the mixture before processing (Comparative Example 1). 3.9-fold or more and about 3.6-fold or more (FIG. 3).
또한 본 발명에 따른 산양삼새싹의 버섯균사체 발효조성물은 진세노사이드 F3, Rg2, F1, 프로토파낙사트리올, Rd, Rd2, F1, Rg3, 및 프로토파낙사디올, 총 페놀릭스 및 총 플라보노이드 등의 생리활성물질의 함량이 강화되어, 증진된 항산화 활성, 항당뇨 활성 및 항비만 활성을 갖는다 (표 1, 도 3, 도 4 ~ 5, 및 도 6 ~ 10).In addition, the mushroom mycelium fermented composition of wild goat sprouts according to the present invention is ginsenosides F3, Rg2, F1, protopanaxatriol, Rd, Rd2, F1, Rg3, and protopanaxadiol, total phenolics and total flavonoids, etc. The content of physiologically active substances is enhanced, and it has enhanced antioxidant activity, antidiabetic activity, and antiobesity activity (Table 1, FIG. 3, FIGS. 4 to 5, and FIGS. 6 to 10).
본 발명의 또 다른 목적을 달성하기 위하여, 본 발명은 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 증진된 산양삼새싹의 버섯균사체 발효조성물의 제조방법을 제공한다. In order to achieve another object of the present invention, the present invention is fermented mushroom mycelium of goat ginseng sprouts with enhanced ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol. A method for preparing the composition is provided.
구체적으로 상기 방법은 Specifically, the method
ⅰ) 산양삼새싹 90~94 중량% 및 콩 6~10 중량%를 혼합한 후 물을 5~10배(v/w)으로 혼합하여 5~7시간 수화하는 단계;i) hydrating for 5 to 7 hours by mixing 90 to 94% by weight of wild goat sprouts and 6 to 10% by weight of soybeans and then mixing with water 5 to 10 times (v / w);
ⅱ) 100~120℃에서 30 ~ 60분 증자하는 단계; 및 ii) steaming for 30 to 60 minutes at 100 to 120°C; and
ⅲ) 동충하초버섯 또는 팽이버섯의 균사체를 3~10%(v/w) 농도로 접종하여 20~30℃에서 8~12일간 발효하는 단계를 포함한다.iii) inoculating the mycelium of Cordyceps sinensis or Enoki mushroom at a concentration of 3 to 10% (v/w) and fermenting at 20 to 30 ° C for 8 to 12 days.
본 발명의 제조방법에서, 산양삼새싹 및 콩의 혼합물의 중량비, 수화, 증자, 동충하초버섯 및 팽이버섯의 버섯균사체, 및 발효는 상기에서 정의된 바와 같다. In the production method of the present invention, the weight ratio, hydration, steaming, mushroom mycelium of cordyceps sinensis and enoki mushroom, and fermentation of the mixture of wild goat sprouts and soybeans are as defined above.
동충하초버섯 및 팽이버섯의 균사체의 원활한 발효를 위하여 발효 전에 산양삼새싹 및 콩의 혼합물에 물을 첨가하여 수화할 수 있다.For smooth fermentation of the mycelium of Cordyceps sinensis and Enoki mushroom, water can be added to the mixture of wild goat shoots and soybeans before fermentation to hydrate them.
발효 전에, 살균하기 위하여 증자 처리될 수 있다. 증자는 100~120℃에서 30~60분 증자하는 것이 바람직하고, 가장 바람직하게는 120℃에서 30분 증자한다. Prior to fermentation, it may be steamed to sterilize. It is preferable to steam for 30 to 60 minutes at 100 ~ 120 ℃, most preferably for 30 minutes at 120 ℃.
본 발명의 또 다른 목적에 따라서, 본 발명은 상기 제조방법에 의해 제조된 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 증진된 산양삼새싹의 버섯균사체 발효조성물을 포함하는 기능성식품을 제공한다.According to another object of the present invention, the present invention is a mushroom of wild ginseng bud with enhanced F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol prepared by the above production method It provides a functional food containing a mycelium fermentation composition.
본 발명에 따른 기능성 식품은 우수한 항산화 활성, 당뇨 개선 및 비만 개선 효과를 갖는다 (도 4a~도 6). The functional food according to the present invention has excellent antioxidant activity, diabetes and obesity improvement effects (Figs. 4a to 6).
본 발명의 또 다른 목적에 따라서, 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 증진된 산양삼새싹의 버섯균사체 발효조성물을 포함하는 화장품을 제공한다.According to another object of the present invention, cosmetics containing a fermented composition of mushroom mycelium of wild goat sprouts with enhanced ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol provides
본 발명의 식품 또는 화장품은 본 발명의 발효조성물 또는 이의 추출물을 그대로 첨가하거나 다른 식품 성분과 혼합되어 제조될 수 있고, 통상적인 방법에 따라 적절하게 제조될 수 있다.The food or cosmetic of the present invention may be prepared by adding the fermented composition or an extract thereof of the present invention as it is or by mixing with other food ingredients, and may be appropriately prepared according to a conventional method.
본 발명에서 상기 식품의 종류는 특별히 제한되지 않으며, 환제, 정제, 캡슐제, 발효차, 발효식품 (김치류, 피클류 등), 발효음료 (파우치제, 드링크제 등) 등일 수 있으나, 이에 제한되지는 않는다. 화장품의 종류는 마스크팩, 스킨, 로션, 크림 등일 수 있으나, 이에 제한되지는 않는다. In the present invention, the type of food is not particularly limited, and may include pills, tablets, capsules, fermented tea, fermented foods (kimchi, pickles, etc.), fermented beverages (pouches, drinks, etc.), but is not limited thereto. don't Types of cosmetics may include mask packs, toners, lotions, creams, and the like, but are not limited thereto.
본 발명에 따른 산양삼새싹의 버섯균사체 발효조성물은 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 고함량으로 함유되어 기능성식품 및 화장품의 소재로 사용될 수 있다.The mushroom mycelium fermented composition of wild ginseng sprouts according to the present invention contains ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol in high content, making it suitable for functional foods and cosmetics. material can be used.
또한 본 발명에 따른 기능성식품 또는 화장품은 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올의 함량이 높으며, 더불어 우수한 항산화 활성, 알파-글루코시다아제 저해활성 및 췌장-리파아제 저해활성을 가져서, 지방생성 억제효과, 체중 조절, 콜레스테롤 저하, 고지혈증 개선, 동맥경화 완화, 당뇨병 개선, 비만 개선, 혈액순환 개선, 면역력 개선, 피부 미용, 여성 갱년기 증후군 개선용으로 유용하다. In addition, the functional food or cosmetic according to the present invention has a high content of ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol, as well as excellent antioxidant activity, alpha-glucose It has sidase inhibitory activity and pancreatic-lipase inhibitory activity, so it has anti-adipogenesis effect, weight control, cholesterol lowering, hyperlipidemia improvement, arteriosclerosis relief, diabetes improvement, obesity improvement, blood circulation improvement, immunity improvement, skin beauty, female menopausal syndrome useful for improvement
도 1은 본 발명에 따른 버섯균사체 발효조성물의 제조 공정도의 일례이다.
도 2는 진세노사이드 HPLC 크로마토그램을 나타낸 것이다. 도 2a는 비교예인 산양삼새싹 원료의 진세노사이드 HPLC 크로마토그램이며, 도 2b는 실시예 1인 동충하초버섯 균사체 발효조성물의 진세노사이드 HPLC 크로마토그램이며, 도 2c는 실시예 2인 팽이버섯 균사체 발효조성물의 진세노사이드 HPLC 크로마토그램이다.
도 3은 본 발명에 따른 발효조성물의 프로토파낙사트리올 계열, 프로토파낙사디올 계열, 및 총 진세노사이드 함량을 나타낸 것이다.
도 4는 본 발명에 따른 발효조성물의 총 페놀릭스 함량을 나타낸 것이다.
도 5는 본 발명에 따른 발효조성물의 총 플라보노이드 함량을 나타낸 것이다.
도 6은 본 발명에 따른 발효조성물의 DPPH 라디칼 소거활성을 나타낸 것이다,
도 7은 본 발명에 따른 발효조성물의 ABTS 라디칼 소거활성을 나타낸 것이다.
도 8은 본 발명에 따른 발효조성물의 환원력(FRAP)을 나타낸 것이다.
도 9은 본 발명에 따른 발효조성물의 알파-글루코시다아제 저해활성을 나타낸 것이다.
도 10은 본 발명에 따른 발효조성물의 췌장-리파아제 저해활성을 나타낸 것이다.1 is an example of a manufacturing process diagram of a mushroom mycelium fermentation composition according to the present invention.
Figure 2 shows a ginsenoside HPLC chromatogram. Figure 2a is a ginsenoside HPLC chromatogram of a raw material of wild ginseng sprouts as a comparative example, Figure 2b is a ginsenoside HPLC chromatogram of the mycelium fermented composition of Cordyceps mushroom mycelium of Example 1, Figure 2c is the fermented enoki mushroom mycelium composition of Example 2 This is the ginsenoside HPLC chromatogram of
Figure 3 shows the protopanaxatriol series, protopanaxadiol series, and total ginsenoside contents of the fermented composition according to the present invention.
Figure 4 shows the total phenolics content of the fermentation composition according to the present invention.
Figure 5 shows the total flavonoid content of the fermentation composition according to the present invention.
Figure 6 shows the DPPH radical scavenging activity of the fermentation composition according to the present invention,
7 shows the ABTS radical scavenging activity of the fermentation composition according to the present invention.
8 shows the reducing power (FRAP) of the fermented composition according to the present invention.
Figure 9 shows the alpha-glucosidase inhibitory activity of the fermented composition according to the present invention.
10 shows the pancreatic-lipase inhibitory activity of the fermented composition according to the present invention.
다음의 실시예들에 의해 본 발명이 더 상세히 설명된다. 이들 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 범위가 이들에 의해 제한되어서는 안된다.The present invention is explained in more detail by the following examples. These examples are intended to illustrate the present invention, and the scope of the present invention should not be limited thereto.
제조예 1: 발효조성물 제조Preparation Example 1: Preparation of fermentation composition
산양삼새싹은 2020년도 함양군 백전면 일대에서 재배된 것을 농업회사법인 주식회사 진생바이오로부터 공급받아 사용하였다. 콩(오리알태콩)은 진주시 소재 대형마트에서 구입하여 사용하였다.Sanyang ginseng sprouts grown in Baekjeon-myeon, Hamyang-gun in 2020 were supplied from Ginseng Bio Co., Ltd., an agricultural corporation, and used. Beans (duck roe beans) were purchased and used at a large mart in Jinju City.
버섯균사체는 한국생물자원센터, 한국미생물보존센터, 또는 경상남도농업기술원으로부터 영지버섯, 새송이버섯, 느타리버섯, 동충하초버섯 및 팽이버섯의 균사체를 분양받아 활성화시켜 사용하였다. 버섯균사체 계대 배양은 Potato Dextrose broth/agar(PDB/PDA, BD-Difco사, Sparks, MD, USA)를 사용하였다.Mushroom mycelia were purchased from the Korea Center for Biological Resources, the Korea Center for Microbial Conservation, or the Gyeongsangnam-do Agricultural Research and Extension Services, and mycelia of Ganoderma lucidum, king oyster mushroom, oyster mushroom, cordyceps mushroom, and enoki mushroom were used after being activated. For subculture of mushroom mycelium, Potato Dextrose broth/agar (PDB/PDA, BD-Difco, Sparks, MD, USA) was used.
산양삼새싹은 흐르는 물에 3회 세척한 후 약 1 cm 정도로 절단한 후 55℃에서 3일간 건조하여 준비하였다. 건조 산양삼과 콩을 9:1의 중량비로 혼합하여 산양삼새싹 혼합시료를 준비하였다.Wild ginseng sprouts were prepared by washing three times in running water, cutting them to about 1 cm, and then drying them at 55 ° C. for 3 days. A mixed sample of wild ginseng sprouts was prepared by mixing dried wild ginseng and soybeans at a weight ratio of 9:1.
산양삼새싹 혼합시료에 10배(v/w) 정제수를 첨가하고 6시간 수화시켜 수분 함량을 약 40% 정도 되게 조정한 후 고압멸균기를 이용하여 120℃에서 30분 동안 증자 처리하고 상기에서 준비된 버섯균사체 배양액을 각각 5%(v/w) 접종한 뒤 25℃에서 10일간 발효를 진행하여 발효조성물을 얻었다 (도 1). After adding 10 times (v/w) purified water to the mixed sample of wild goat sprouts and hydrating for 6 hours to adjust the moisture content to about 40%, steaming was performed at 120 ° C for 30 minutes using a high-pressure sterilizer, and the mushroom mycelium prepared above After inoculating the culture medium at 5% (v/w), fermentation was performed at 25° C. for 10 days to obtain a fermentation composition (FIG. 1).
비교를 위하여, 건조 산양삼과 콩을 9:1의 중량비로 혼합하여 산양삼새싹 혼합시료 조성물(비교예 1)을 준비하였다.For comparison, a mixed sample composition (Comparative Example 1) was prepared by mixing dried wild ginseng and soybeans at a weight ratio of 9:1.
참조예: 분석시료Reference example: analysis sample
실시예 1의 발효조성물 (동충하초버섯 균사체로 발효), 실시예 2의 발효조성물 (팽이버섯 균사체로 발효), 비교예 1의 조성물 (산양삼새싹 혼합시료), 비교예 2의 발효조성물 (영지버섯 균사체로 발효), 비교예 3의 발효조성물 (새송이버섯 균사체로 발효), 비교예 4의 발효조성물 (느타리버섯 균사체로 발효)을 각각 55℃에서 3일간 건조하여 분쇄시켜 분말 시료를 준비하였다. Fermentation composition of Example 1 (fermentation with cordyceps mushroom mycelium), fermentation composition of Example 2 (fermentation with enoki mushroom mycelium), composition of Comparative Example 1 (mixed sample of wild goat sprouts), fermentation composition of Comparative Example 2 (Ganoderma lucidum mycelium Fermented with oyster mushroom), the fermentation composition of Comparative Example 3 (fermented with king oyster mushroom mycelium), and the fermentation composition of Comparative Example 4 (fermented with oyster mushroom mycelium) were dried at 55 ° C. for 3 days and pulverized to prepare powder samples.
분말 시료 1 g에 50% 메탄올을 20배 첨가하여 12시간 동안 추출한 완전히 농축한 후 50% 메탄올을 2 ml을 첨가하여 녹인 후 0.45 μm 여과 필터로 여과하여 HPLC 베일에 담아 진세노사이드를 분석하였다. 50% methanol was added to 1 g of the
분말 시료 10 g에 50% 주정을 20배 첨가하여 12시간 동안 추출한 일부 0.45 μm 여과 필터로 여과하여 총 페놀릭스와 총 플라보노이드 분석에 사용하였고 나머지 추출액은 감압여과기를 이용해 여과하고 감압농축기를 이용하여 완전 농축시킨 후 동결건조기(FD-1000, Tokyo, Rikakikai, Japan)를 이용하여 동결건조하였다. 최종 동결건조된 시료에 50% 주정을 첨가하여 시료농도가 0.5, 1.0 및 2.0 mg/mL이 되게 제조한 후 하기 생리활성시험에 사용하였다.50% alcohol was added 20 times to 10 g of the powder sample, extracted for 12 hours, filtered through a 0.45 μm filtration filter, and used for analysis of total phenolics and total flavonoids. The remaining extract was filtered using a vacuum filter and completely purified using a vacuum concentrator. After concentration, it was freeze-dried using a freeze dryer (FD-1000, Tokyo, Rikakikai, Japan). 50% alcohol was added to the final freeze-dried sample to prepare sample concentrations of 0.5, 1.0 and 2.0 mg/mL, and then used in the following physiological activity test.
시험예 1: 진세노사이드 함량 분석Test Example 1: Analysis of ginsenoside content
진세노사이드 분석은 기능성식품분석법의 홍삼 사포닌 분석법에 기술된 방법을 변형하여 고압액체크로마토그래피(HPLC, high press liquid chromatograph)로 분석하였다. 분석 컬럼은 TSKgel ODS-100Z을 사용하여 시료주입량 10 ㎕, 온도는 30℃, 측정파장은 203 nm, 유속은 1.0 ㎖/min으로 하였고 이동상으로는 A용액은 HPLC water, B용액은 아세토니트릴을 사용하였다. HPLC 분석 조건은 이동상 용액은 0분때 A용액 81% : B용액 19%로 흘려주고 15분때에는 A용액 80% : B용액 20%로 흘려주고 40분때 A용액 77% : B용액 23%, 40분때 A용액 77% : B용액 23%, 42분때 A용액 70% : B용액 30%, 75분때에 A용액 65% : B용액 35%, 80분때에 A용액 30% : B용액 70%, 90분때에 A용액 10% : B용액 90%로 이동상을 흘려주었다. 실시예 1, 실시예 2 및 비교예 1의 진세노사이드 HPLC 크로마토그램을 각각 도 2a ~ 도 2c에 나타냈고, 비교예 1, 실시예 1 및 실시예 2에 대해 분석된 F3, Rg2, F1, 프로토파낙사트리올 (PPT), Rd, Rd2, F2, Rg3, 및 프로토파낙사디올 (PPD) 함량을 표 1에 나타내었다. 또한 비교예 1~4, 실시예 1 및 실시예 2에 대한 프로토파낙사트리올 계열(Rg2, F1, 및 PPT) 진세노사이드, 프로토파낙사디올 계열(Rd, Rd2, F2, Rg3, 및 PPD) 진세노사이드, 및 총 진세노사이드 함량을 산출하여 도 3에 나타냈다. Ginsenoside analysis was analyzed by high pressure liquid chromatography (HPLC) by modifying the method described in the functional food analysis method for red ginseng saponin analysis. The analysis column was TSKgel ODS-100Z, and the sample injection amount was 10 μl, the temperature was 30 ° C, the measurement wavelength was 203 nm, and the flow rate was 1.0 ml / min. As the mobile phase, HPLC water was used as solution A and acetonitrile was used as solution B. . The HPLC analysis conditions are: 81% of A solution: 19% of B solution at 0 minutes, 80% of A solution: 20% of B solution at 15 minutes, 77% of A solution at 40 minutes: 23% of B solution at 40 minutes 77% of solution A: 23% of solution B, 42 minutes 70% of solution A: 30% of solution B, 65% of solution A at 75 minutes: 35% of solution B, 30% of solution A at 80 minutes: 70% of solution B, 90 minutes The mobile phase was flowed with A
(원료)Comparative Example 1
(Raw material)
nd: 검출되지 않음.All experiments were repeated 5 times and displayed as the average value.
nd: not detected.
도 2a ~ 도 2c에 나타낸 바와 같이, 비교예 1의 조성물에서는 F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3, 및 PPD 피크가 낮게 나타난 반면에, 본 발명에 따른 실시예 1의 동충하초버섯 균사체 발효조성물 및 실시예 2의 팽이버섯 균사체 발효조성물에서는 F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3, 및 PPD 피크가 현저히 높아진 것을 확인할 수 있다. As shown in Figures 2a to 2c, the composition of Comparative Example 1 showed low F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3, and PPD peaks, whereas Cordyceps sinensis of Example 1 according to the present invention It can be seen that the F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3, and PPD peaks in the mushroom mycelium fermentation composition and the enoki mushroom mycelium fermentation composition of Example 2 were significantly increased.
또한, 표 1에 나타낸 바와 같이, 가공되지 않은 산양산새싹 혼합원료인 비교예 1의 경우는 F3는 검출되지 않았고, Rg2, F1, PPT, Rd, Rd2, F2, Rg3, 및 PPD 함량은 각각 0.48 mg/g, 0.66 mg/g, 0.14 mg/g, 2.65 mg/g, 0.37 mg/g, 0.77 mg/g, 0.17 mg/g, 및 1.84 mg/g 이었으나, 실시예 1의 동충하초버섯 균사체 발효조성물의 경우 F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3 및 PPD 함량은 각각 0.23 mg/g, 1.31 mg/g, 1.35 mg/g, 0.28 mg/g, 8.13 mg/g, 1.10 mg/g, 2.48 mg/g, 1.16 mg/g 및 9.78 mg/g로 증가됨을 확인할 수 있고, 실시예 2의 팽이버섯 균사체 발효조성물의 경우 F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3 및 PPD 함량은 각각 0.46 mg/g, 1.80 mg/g, 1.27 mg/g, 0.62 mg/g, 6.59 mg/g, 4.17 mg/g, 5.33 mg/g, 2.86 mg/g 및 4.53 mg/g로 증가됨을 확인할 수 있다. In addition, as shown in Table 1, in the case of Comparative Example 1, which is a mixed raw material for unprocessed goat buds, F3 was not detected, and the Rg2, F1, PPT, Rd, Rd2, F2, Rg3, and PPD contents were 0.48, respectively. mg / g, 0.66 mg / g, 0.14 mg / g, 2.65 mg / g, 0.37 mg / g, 0.77 mg / g, 0.17 mg / g, and 1.84 mg / g, but Cordyceps mushroom mycelium fermented composition of Example 1 In the case of F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3 and PPD contents were 0.23 mg/g, 1.31 mg/g, 1.35 mg/g, 0.28 mg/g, 8.13 mg/g, 1.10 mg/g, respectively. g, 2.48 mg/g, 1.16 mg/g and 9.78 mg/g, and in the case of the enoki mushroom mycelium fermented composition of Example 2, F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3 and The PPD content increased to 0.46 mg/g, 1.80 mg/g, 1.27 mg/g, 0.62 mg/g, 6.59 mg/g, 4.17 mg/g, 5.33 mg/g, 2.86 mg/g and 4.53 mg/g, respectively. can confirm.
도 3에 도시된 바와 같이, 가공되지 않은 산양산 혼합원료인 비교예 1의 프로토파낙사트리올 계열(F3, Rg2, F1, 및 PPT) 진세노사이드, 프로토파낙사디올 계열(Rd, Rd2, F2, Rg3, 및 PPD) 진세노사이드, 및 총 진세노사이드 함량은 각각 1.28 mg/g, 5.80 mg/g, 및 7.08 mg/g이었으나, 실시예 1의 동충하초버섯 균사체 발효조성물의 프로토파낙사트리올 계열(F3, Rg2, F1, 및 PPT) 진세노사이드, 프로토파낙사디올 계열(Rd, Rd2, F2, Rg3, 및 PPD) 진세노사이드 및 총 진세노사이드 함량은 3.17 mg/g, 22.65 mg/g 및 25.82 mg/g으로 비교예 1에 비하여 각각 약 2.4배, 3.9배 및 3.6배 증진되었음을 확인할 수 있다. 실시예 2의 팽이버섯 균사체 발효조성물의 프로토파낙사트리올 계열(F3, Rg2, F1, 및 PPT) 진세노사이드, 프로토파낙사디올 계열(Rd, Rd2, F2, Rg3, 및 PPD) 진세노사이드 및 총 진세노사이드 함량은 4.15 mg/g, 23.48 mg/g 및 27.63 mg/g으로 비교예 1에 비하여 각각 약 3.2배, 4배 및 3.9배 증진되었음을 확인할 수 있다. As shown in FIG. 3, protopanaxatriol series (F3, Rg2, F1, and PPT) ginsenosides, protopanaxadiol series (Rd, Rd2, F2, Rg3, and PPD) ginsenosides, and total ginsenoside contents were 1.28 mg/g, 5.80 mg/g, and 7.08 mg/g, respectively, but Protopanaxatri of the Cordyceps mushroom mycelium fermented composition of Example 1 All-type (F3, Rg2, F1, and PPT) ginsenosides, protopanaxadiol-type (Rd, Rd2, F2, Rg3, and PPD) ginsenosides and total ginsenoside contents were 3.17 mg/g, 22.65 mg / g and 25.82 mg / g, respectively, compared to Comparative Example 1, it can be confirmed that the enhancement was about 2.4 times, 3.9 times, and 3.6 times. Protopanaxatriol-based (F3, Rg2, F1, and PPT) ginsenosides, protopanaxadiol-based (Rd, Rd2, F2, Rg3, and PPD) ginsenosides of the fermented enoki mushroom mycelium composition of Example 2 And the total ginsenoside content was 4.15 mg / g, 23.48 mg / g, and 27.63 mg / g, respectively, compared to Comparative Example 1.
또한 비교예 2 내지 비교예 4의 프로토파낙사디올 계열(Rd, Rd2, F2, Rg3, 및 PPD) 진세노사이드 및 총 진세노사이드 함량 (각각 12.02 ~ 14.06 mg/g 및 14.68 ~ 18.39 mg/g)에 비하여도 본 발명에 따른 실시예 1 및 실시예 2의 경우는 각각 약 1.6배 이상 및 약 1.6배 이상 증진되었음을 확인할 수 있다. In addition, the protopanaxadiol series (Rd, Rd2, F2, Rg3, and PPD) ginsenosides and total ginsenoside contents of Comparative Examples 2 to 4 (12.02 to 14.06 mg/g and 14.68 to 18.39 mg/g, respectively) ), it can be confirmed that in the case of Example 1 and Example 2 according to the present invention, the improvement was about 1.6 times or more and about 1.6 times or more, respectively.
따라서 동충하초버섯 및 팽이버섯의 균사체로 발효된 본 발명에 따른 산양삼새싹 발효조성물은 진세노사이드 F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3 및 PPD의 함량이 현저히 강화됨을 알 수 있다. Therefore, it can be seen that the content of ginsenosides F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3 and PPD in the fermented wild ginseng sprout composition according to the present invention fermented with the mycelium of Cordyceps sinensis and Enoki mushroom is significantly enhanced.
시험예 2. 생리활성성분 함량 분석Test Example 2. Analysis of bioactive component content
항산화 활성 등을 나타내는 생리활성성분인 총 페놀릭스 및 총 플라보노이드 함량 함량을 분석하였다.The total phenolics and total flavonoid contents, which are physiologically active components showing antioxidant activity, were analyzed.
<총 페놀릭스 함량><Total phenolic content>
분석시료를 시험관에 0.5 ml 분주하고 여기에 25% Na2CO3 용액 0.5 ml를 첨가하여 3분간 정치시킨 후, 2N Folin-Ciocalteu 페놀 시약 0.25 ml를 첨가하여 혼합한 다음 30℃에서 1시간 동안 정치시킨 후 750 nm에서 분광광도계를 사용하여 750nm에서 흡광도를 측정하였다. 이때 총 페놀릭스 함량은 갈산(Gallic acid)을 이용하여 작성한 표준곡선으로부터 함량을 구하여 갈산에 상당하는 양으로 계산하였고 그 결과를 도 4에 나타냈다.0.5 ml of the analysis sample was dispensed into a test tube, 0.5 ml of a 25% Na 2 CO 3 solution was added thereto, allowed to stand for 3 minutes, 0.25 ml of 2N Folin-Ciocalteu phenol reagent was added, mixed, and allowed to stand at 30°C for 1 hour. After that, absorbance was measured at 750 nm using a spectrophotometer. At this time, the total phenolic content was calculated as the amount corresponding to gallic acid by obtaining the content from the standard curve prepared using gallic acid, and the results are shown in FIG.
도 4에 나타낸 바와 같이, 총 페놀릭스 함량은 비교예 1은 3.28 mg/g이었으며, 실시예 1은 6.08 mg/g 및 실시예 2는 6.69 mg/g으로 나타나, 본 발명에 따른 발효조성물은 총 페놀릭스 함량이 현저히 증진됨을 확인할 수 있다. As shown in FIG. 4, the total phenolics content was 3.28 mg/g in Comparative Example 1, 6.08 mg/g in Example 1 and 6.69 mg/g in Example 2, and the fermented composition according to the present invention had a total It can be seen that the phenolics content is significantly increased.
<총 플라보노이드 함량><Total flavonoid content>
분석시료 0.5 ml에 디에틸렌글리콜 1.0 ml를 분주한 후 1 N NaOH 0.01 ml를 첨가한 후 하여 37℃ 항온수조에서 1시간 방치 후 420 nm에서 분광광도계로 흡광도를 측정하였다. 이때 총 플라보노이드스 함량은 루틴(rutin)을 이용하여 작성한 표준곡선으로부터 함량을 구하였고 그 결과는 도 5에 나타내었다. After dispensing 1.0 ml of diethylene glycol to 0.5 ml of the analysis sample, 0.01 ml of 1 N NaOH was added, and the mixture was left in a constant temperature water bath at 37° C. for 1 hour, and then the absorbance was measured with a spectrophotometer at 420 nm. At this time, the total flavonoids content was obtained from a standard curve prepared using rutin, and the results are shown in FIG. 5.
도 5에 나타낸 바와 같이, 총 플라보노이드 함량도, 비교예 1은 1.36 mg/g, 실시예 1은 2.43 mg/g 및 실시예 2는 2.67 mg/g으로 나타나, 본 발명에 따른 발효조성물은 총 플라보노이드의 함량도 크게 증가하는 것을 확인할 수 있다.As shown in FIG. 5, the total flavonoid content was 1.36 mg/g in Comparative Example 1, 2.43 mg/g in Example 1 and 2.67 mg/g in Example 2, and the fermented composition according to the present invention had a total flavonoid content. It can be seen that the content of
시험예 3. 항산화 활성 분석Test Example 3. Antioxidant activity analysis
항산화 활성은 DPPH 라디칼 소거활성, ABTS 라디칼 소거활성, 및 FRAP 환원력을 측정하여 분석하였다.Antioxidant activity was analyzed by measuring DPPH radical scavenging activity, ABTS radical scavenging activity, and FRAP reducing power.
참고예에서와 같이 실시예 1, 실시예 2 및 비교예 1~비교예 4의 분석시료를 0.5, 1, 및 2 mg/ml 농도로 제조하여 사용하였다.As in the Reference Example, the analysis samples of Examples 1, 2, and Comparative Examples 1 to 4 were prepared and used at concentrations of 0.5, 1, and 2 mg/ml.
<DPPH 라디칼 소거활성><DPPH radical scavenging activity>
각각의 시료 0.2 ml에 DPPH 메탄올 용액(1.5×10-4 M) 0.8 ml를 첨가하여 10초간 교반후 암실에서 30분간 방치한 후 525 nm에서 흡광도를 측정하여 수행하였다. DPPH 라디칼 소거활성의 음성 대조구는 시료 대신 추출용매를 사용하여 동일한 방법으로 진행하여 흡광도의 차이를 다음과 같은 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 6에 도시하였다. 0.8 ml of DPPH methanol solution (1.5×10 -4 M) was added to 0.2 ml of each sample, stirred for 10 seconds, left in the dark for 30 minutes, and then absorbance was measured at 525 nm. The negative control of DPPH radical scavenging activity was performed in the same way using an extraction solvent instead of the sample, and the difference in absorbance was calculated as a percentage (%) by the following equation, and the results are shown in FIG. 6.
라디칼 소거활성(%) = [1-(음성대조구 흡광도 ÷실험구 흡광도)] ×100Radical scavenging activity (%) = [1-(negative control absorbance ÷ test absorbance)] × 100
도 6에 나타난 바와 같이, DPPH 라디칼 소거활성은 1 mg/ml의 농도에서 비교예 1, 비교예 2, 비교예 3, 비교예 4, 실시예 1 및 실시예 2는 각각 17.81%, 58.01%, 62.18%, 66.33%, 72.05%, 및 78.15%의 활성을 나타내 실시예 1 및 실시예 2의 발효조성물이 현저히 높은 활성을 보였다. As shown in FIG. 6, the DPPH radical scavenging activity at a concentration of 1 mg/ml was 17.81%, 58.01%, 62.18%, 66.33%, 72.05%, and 78.15% of activity, respectively, the fermented compositions of Examples 1 and 2 showed significantly higher activity.
<ABTS 라디칼 소거활성><ABTS radical scavenging activity>
7 mM ABTS+와 2.45 mM K2S2O8를 1:1 비율로 섞어 암실에서 12~16시간 반응시킨 후 메탄올과 1:88 비율로 섞어 732 nm에서 대조구의 흡광도 값이 0.7±0.02가 되도록 조절한 ABTS+ 용액을 사용하였다. 각각의 시료 0.1 ml와 ABTS+ 용액 0.9 ml를 첨가하여 혼합한 후 3분간 정치 후 즉시 732 nm에서 분광광도계를 사용하여 흡광도를 측정하였다. 음성대조구 실험은 시료 대신에 추출용매를 취하여 진행하였으며 실험구와 음성 대조구의 흡광도를 구하여 상기 식에 의해 백분율(%)로 산출하여 그 결과를 도 7에 나타냈다. Mix 7 mM ABTS + and 2.45 mM K 2 S 2 O 8 at a ratio of 1:1 and react in the dark for 12 to 16 hours, then mix with methanol at a ratio of 1:88 to obtain a control absorbance value of 0.7±0.02 at 732 nm. A conditioned ABTS + solution was used. 0.1 ml of each sample and 0.9 ml of ABTS + solution were added and mixed, and then allowed to stand for 3 minutes, and the absorbance was immediately measured at 732 nm using a spectrophotometer. The negative control experiment was conducted by taking an extraction solvent instead of the sample, and the absorbance of the experimental group and the negative control group was calculated and calculated in percentage (%) by the above formula, and the results are shown in FIG. 7.
도 7에 나타난 바와 같이, ABTS 라디칼 소거활성은 0.5 mg/ml의 농도에서 비교예 1, 비교예 2, 비교예 3, 비교예 4, 실시예 1 및 실시예 2는 각각 32.93%, 63.61%, 70.73%, 74.76%, 83.74%, 및 90.75%의 활성을 나타내 실시예 1 및 실시예 2의 발효조성물이 현저히 높은 활성을 보였다.As shown in FIG. 7, the ABTS radical scavenging activity at a concentration of 0.5 mg/ml was 32.93%, 63.61%, 70.73%, 74.76%, 83.74%, and 90.75% of the activity, respectively, the fermented compositions of Examples 1 and 2 showed significantly higher activity.
<FRAP 환원력 분석><FRAP reducing power analysis>
FRAP 환원력 분석에서 반응액으로는 30 mM 아세테이트 완충액(pH 3.6), 40 mM 염산에 녹인 10 mM 2,4,6-트리피리딜-s-트리아진(TPTZ, T1253, C18H12N6, MW312.33) 및 20 mM FeCl3(F7134, MW 162.20, in DW)를 준비하였으며, 아세테이트 완충액, TPTZ 용액 및 FeCl3 용액을 10:1:1 (v/v/v)로 혼합하여 37 ℃에서 15분간 예비반응을 시켜두었다. 각각의 시료 0.05 ml에 FRAP 시약 0.95ml를 첨가하여 37 ℃에서 약 15분간 반응시키고 590 nm에서 흡광도를 측정하여 그 결과를 도 8에 나타냈다.In the FRAP reducing power assay, the reaction solution was 30 mM acetate buffer (pH 3.6) and 10 mM 2,4,6-tripyridyl-s-triazine (TPTZ, T1253, C1 8 H 12 N 6 , dissolved in 40 mM hydrochloric acid). MW312.33) and 20 mM FeCl 3 (F7134, MW 162.20, in DW) were prepared, and acetate buffer, TPTZ solution and FeCl 3 solution were mixed at 10:1:1 (v/v/v) at 37 °C. A pre-reaction was allowed for 15 minutes. 0.95 ml of FRAP reagent was added to 0.05 ml of each sample, reacted at 37° C. for about 15 minutes, and absorbance was measured at 590 nm. The results are shown in FIG. 8 .
도 8에 나타난 바와 같이, FRAP 환원력은 1 mg/ml의 농도에서 비교예 1, 비교예 2, 비교예 3, 비교예 4, 실시예 1 및 실시예 2는 각각 0.44, 0.81, 0.88, 0.98, 1.07, 1.21 OD593 nm의 활성을 나타내 실시예 1 및 실시예 2의 발효조성물이 현저히 높은 활성을 보였다.As shown in FIG. 8, the FRAP reducing powers of Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4, Example 1 and Example 2 at a concentration of 1 mg/ml were 0.44, 0.81, 0.88, 0.98, 1.07, 1.21 OD of 593 nm, the fermented composition of Example 1 and Example 2 showed a remarkably high activity.
이들 결과로부터 본 발명에 따른 발효조성물은 항산화 활성이 현저히 증진됨을 알 수 있다.From these results, it can be seen that the antioxidant activity of the fermented composition according to the present invention is significantly enhanced.
시험예 4: 소화효소 저해활성 검정Test Example 4: Digestive enzyme inhibitory activity assay
본 발명에 따른 산양삼새싹의 버섯균사체 발효조성물에 대해 항당뇨(당뇨 개선) 효과의 지표인 알파-글루코시다아제 저해활성을 검정하였고, 항비만(비만 개선) 지표인 췌장 리파아제 저해활성을 검정하였다.Alpha-glucosidase inhibitory activity, which is an indicator of anti-diabetic (diabetic improvement) effect, was assayed for the mushroom mycelium fermented composition of wild goat sprouts according to the present invention, and pancreatic lipase inhibitory activity, which is an anti-obesity (obesity improvement) index, was assayed.
<알파-글루코시다아제 저해활성><Alpha-glucosidase inhibitory activity>
분석시료 30 ㎕에 알파-글루코시다아제 (0.5 U/ml) 효소용액 70 ㎕, 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37℃에서 10분간 예비반응하였다. 이후 인산나트륨 완충용액(pH 6.8)에 녹인 p-NPG (10 mM) 100 ㎕를 첨가하여 다시 37℃에서 10분 반응시켰으며 반응액에 Na2CO3 (100 mM) 750 ㎕를 첨가해 반응을 정지시킨 후 420 nm에서 분광광도계를 이용하여 흡광도를 측정하였다. 음성대조구는 시료 대신에 추출용매를 취하였으며 분석시료 첨가구와 무첨가구 사이의 흡광도 차이를 백분율(%)로 나타내어 그 결과를 도 9에 나타냈다.70 μl of alpha-glucosidase (0.5 U/ml) enzyme solution and 50 μl of 200 mM sodium phosphate buffer solution (pH 6.8) were mixed with 30 μl of the analysis sample, followed by a preliminary reaction at 37° C. for 10 minutes. Thereafter, 100 μl of p-NPG (10 mM) dissolved in sodium phosphate buffer (pH 6.8) was added and reacted at 37° C. for 10 minutes, and 750 μl of Na 2 CO 3 (100 mM) was added to the reaction solution to After stopping, absorbance was measured using a spectrophotometer at 420 nm. In the negative control group, an extraction solvent was taken instead of the sample, and the difference in absorbance between the sample added and not added was expressed as a percentage (%), and the results are shown in FIG. 9 .
도 9에 도시된 바와 같이, 알파-글루코시다아제 저해활성은 2.0 mg/ml 처리시 비교예 1, 비교예 2, 비교예 3, 비교예 4, 실시예 1 및 실시예 2는 각각 19.84, 35.66, 38.42, 41.71, 48.27, 52.33 %의 활성을 나타내 실시예 1 및 실시예 2의 발효조성물이 현저히 높은 효소 저해활성을 보였다.As shown in FIG. 9, alpha-glucosidase inhibitory activity was 19.84 and 35.66 in Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4, Example 1 and Example 2, respectively, when treated with 2.0 mg/ml. , 38.42, 41.71, 48.27, and 52.33% of the activity, respectively, and the fermented compositions of Examples 1 and 2 showed significantly high enzyme inhibitory activity.
따라서 본 발명에 따른 발효조성물은 알파-글루코시다아제 저해활성이 현저히 증진되어 혈당저하 활성이 우수하여 당뇨 개선효과가 증진됨을 알 수 있다.Therefore, it can be seen that the fermented composition according to the present invention significantly improves the alpha-glucosidase inhibitory activity and has excellent blood sugar lowering activity, thereby enhancing the diabetic improvement effect.
<췌장-리파아제 저해활성><Pancreatic-lipase inhibitory activity>
분석시료 30 ㎕에 췌장 리파아제 (0.5 U/ml) 효소용액 70 ㎕ 및 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37 ℃에서 10분간 예비반응시켰다. 반응 후 인산나트륨 완충용액에 녹인 p-NPB(10 mM) 100 ㎕를 첨가하여 동일하게 10분간 반응시킨 후 100 mM Na2CO3 750 ㎕를 첨가해 반응을 종결시켜 420 nm에서 흡광도를 측정하였다. 음성대조구는 시료 대신에 추출용매를 취하였으며 시료용액의 첨가구와 무첨가구 사이의 흡광도 차이를 백분율(%)로 나타내어 그 결과를 도 10에 나타냈다.70 μl of pancreatic lipase (0.5 U/ml) enzyme solution and 50 μl of 200 mM sodium phosphate buffer (pH 6.8) were mixed with 30 μl of the analysis sample, followed by pre-reaction at 37° C. for 10 minutes. After the reaction, 100 μl of p-NPB (10 mM) dissolved in sodium phosphate buffer was added and reacted for 10 minutes in the same manner, and then the reaction was terminated by the addition of 750 μl of 100 mM Na 2 CO 3 and absorbance was measured at 420 nm. In the negative control group, the extraction solvent was taken instead of the sample, and the difference in absorbance between the added and unadded groups of the sample solution was expressed in percentage (%), and the results are shown in FIG. 10.
도 10에 도시된 바와 같이, 췌장 리파아제 저해활성은 2.0 mg/ml 처리시 비교예 1, 비교예 2, 비교예 3, 비교예 4, 실시예 1 및 실시예 2는 각각 15.46, 35.17, 40.88, 45.66, 51.54, 57.68 %의 활성을 나타내 실시예 1 및 실시예 2의 발효조성물이 현저히 높은 효소 저해활성을 보였다.As shown in FIG. 10, the pancreatic lipase inhibitory activity of Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4, Example 1 and Example 2 were 15.46, 35.17, 40.88, 45.66, 51.54, and 57.68% of the activity, respectively, the fermented compositions of Examples 1 and 2 showed significantly high enzyme inhibitory activity.
따라서 본 발명에 따른 발효조성물은 췌장 리파아제 저해활성이 증진되어 비만 개선효과가 강화됨을 알 수 있다.Therefore, it can be seen that the fermented composition according to the present invention enhances the pancreatic lipase inhibitory activity, thereby enhancing the obesity improvement effect.
상기 활성(기능성) 검정 결과들로부터, 본 발명에 따른 발효조성물은 진세노사이드 F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3 및 PPD의 함량이 증진될 뿐만 아니라, 우수한 항산화 활성, 항당뇨 및 항비만 활성을 가져서 기능성식품 및 화장품의 소재로 유용하다는 것을 알 수 있다.From the above activity (functionality) assay results, the fermented composition according to the present invention not only increases the content of ginsenosides F3, Rg2, F1, PPT, Rd, Rd2, F2, Rg3 and PPD, but also has excellent antioxidant activity, It can be seen that it has diabetes and anti-obesity activity and is useful as a material for functional foods and cosmetics.
Claims (12)
Ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, Protopanaxatriol and Protopa prepared by fermenting a mixture of 90-94 wt% of wild ginseng and 6-10 wt% of soybean with mushroom mycelium Naxadiol-enhanced mushroom mycelium fermented composition of wild goat sprouts.
The method of claim 1, wherein the mushroom mycelium is cordyceps mushroom mycelium or enoki mushroom mycelium, ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol are promoted Mushroom mycelium fermented composition of goat ginseng sprouts.
The method of claim 1, wherein the fermentation composition contains ginsenoside F3 at least 0.23 mg/g, Rg2 at least 1.31 mg/g, F1 at least 1.27 mg/g, and protopanaxatriol at least 0.28 mg/g. That is, ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol are enhanced mushroom mycelium fermented composition of wild goat sprouts.
The method of claim 1, wherein the fermented composition has Rd of 6.59 mg/g or more, Rd2 of 1.10 mg/g or more, F2 of 2.48 mg/g or more, Rg3 of 1.16 mg/g or more, and protopanaxadiol of 4.53 mg / g or more containing, ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol is enhanced mushroom mycelium fermented composition of goat sprouts.
According to claim 1, wherein the fermentation is inoculated with mushroom mycelium at a concentration of 3 to 10% (v / w) and fermented at 20 to 30 ° C for 8 to 12 days, ginsenosides F3, Rg2, F1, Rd, Mushroom mycelium fermented composition of wild goat ginseng with enhanced Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol.
The ginseno according to claim 1, wherein the mixture is hydrated for 5 to 7 hours by mixing 5 to 10 times (v/w) of water before fermentation, and then steamed at 100 to 120 ° C for 30 to 60 minutes. Sides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol fermented mushroom mycelium composition of wild goat sprouts.
ⅰ) 산양삼새싹 90~94 중량% 및 콩 6~10 중량%를 혼합한 후 물을 5~10배(v/w)으로 혼합하여 5~7시간 수화하는 단계;
ⅱ) 100~120℃에서 30~60분 증자하는 단계; 및
ⅲ) 버섯균사체를 3~10%(v/w) 농도로 접종하여 20~30℃에서 8~12일간 발효하는 단계를 포함하는 것인 방법.
A method for producing a fermented wild goat sprout mushroom mycelium composition with enhanced ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol, the method comprising:
i) hydrating for 5 to 7 hours by mixing 90 to 94% by weight of wild goat sprouts and 6 to 10% by weight of soybeans and then mixing with water 5 to 10 times (v / w);
ii) steaming for 30 to 60 minutes at 100 to 120°C; and
iii) A method comprising inoculating mushroom mycelium at a concentration of 3 to 10% (v / w) and fermenting at 20 to 30 ° C. for 8 to 12 days.
The method of claim 7, wherein the mushroom mycelium is cordyceps mushroom mycelium or enoki mushroom mycelium, ginsenosides F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol Method for producing an improved fermented wild goat sprout mushroom mycelium composition.
A functional food having enhanced antioxidant activity comprising the fermented composition according to claim 1.
A functional food for improving diabetes comprising the fermented composition according to claim 1.
A functional food for improving obesity comprising the fermented composition according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210151121A KR20230065499A (en) | 2021-11-05 | 2021-11-05 | A mushroom-mycelium fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210151121A KR20230065499A (en) | 2021-11-05 | 2021-11-05 | A mushroom-mycelium fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230065499A true KR20230065499A (en) | 2023-05-12 |
Family
ID=86385854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210151121A KR20230065499A (en) | 2021-11-05 | 2021-11-05 | A mushroom-mycelium fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230065499A (en) |
-
2021
- 2021-11-05 KR KR1020210151121A patent/KR20230065499A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101015700B1 (en) | Fermentated ginseng and fermentation method for the same | |
KR100945587B1 (en) | Method for preparing of fermented ginseng or fermented red ginseng containing ginsenoside metabolites fermented by cordyceps militaris having various physiological activity | |
Bijalwan et al. | Insights of medicinal mushroom (Ganoderma lucidum): prospects and potential in India | |
KR101482873B1 (en) | Fermentation metabolite of Dendropanax morbiferus produced by liquid-state fermentation and manufacturaring process for the same | |
KR20170133979A (en) | Fertilizer composition of the fruits that increased content of crude saponin and cultivation method of fruits using the same | |
KR100997054B1 (en) | Fermentated woods grown ginseng roots and fermentation method for the same | |
KR101963978B1 (en) | Composition of fermented sprout ginseng having increased ginsenosides Rh2 and compound K, bioactive components, and preparation method thereof | |
CN111321183A (en) | Polysaccharide fermentation composition with anticancer, antiviral, anti-inflammation, osteoblast proliferation promoting and intestinal stem cell proliferation promoting effects and preparation method thereof | |
CN111955721A (en) | Gastrodia elata edible fungus flavor polyphenol liquid plant enzyme formula and preparation method thereof | |
KR20130011511A (en) | Fermented ginseng food manufacturing method | |
KR101372400B1 (en) | A manufacturing method of red ginseng staf4h with enhanced trace ginsenoside | |
KR101963046B1 (en) | Composition of processed ginseng having increased ginsenoside compound K, chlorgenic acid and quercetin, and preparation method thereof | |
CN116463183B (en) | Tartary buckwheat health wine blended with pleurotus eryngii and preparation method thereof | |
CN107173467A (en) | A kind of six fort tea aging methods | |
JPH11228441A (en) | Antioxidant function potentiator for living body | |
KR100643735B1 (en) | Fermented Wine made from Fruit of Araliaceous Shrubs, and Method for producing Thereof | |
KR20230065499A (en) | A mushroom-mycelium fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof | |
KR101084360B1 (en) | A rhus verniciflua stokes using mushroom its manufacture method thereof | |
KR102557683B1 (en) | Fermentation composition of sprouts of mountain-cultivated ginseng having increased ginsenoside Rg3 and Protopanaxadiol, Rutin, Chlorogenic acid and Essential amid acids by using Tricholoma matsutake mycelium and preparation method thereof | |
KR20230064287A (en) | A Monascus fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof | |
KR102545365B1 (en) | Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof | |
KR20190030850A (en) | Platycodon radix composition containing high protocatechuic acid, epicatechin, and oleic acid and enhanced inhibition activities of alpha-glucosidase and pancreatic lipase, and preparation method thereof | |
KR101877225B1 (en) | Method for Manufacturing Tablet Containing Fermented Ginseng and Maca | |
KR100464704B1 (en) | Manufacturing method of fermented alcoholic drink using medicinal and eatable plants having organic germanium and fermented alcoholic drink obtained therefrom | |
KR20200132439A (en) | Method for Manufacturing Fermented Ginseng Tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal |